Kuo D Y, Runowicz C D
Department of Obstetrics and Gynecology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.
Med Oncol. 1995 Jun;12(2):87-94. doi: 10.1007/BF01676708.
Tamoxifen, an estrogen antagonist, is widely used as adjuvant therapy in patients with breast cancer. Its efficacy in increasing survival and reducing recurrence rates has been demonstrated in several European and American studies. However, its effects appear to be tissue specific. Tamoxifen exerts an estrogen effect (agonist) on the endometrium, myometrium and vagina. An increase in uterine cancer has been confirmed in several placebo-controlled clinical trials. Due to the widespread use of this drug, it is timely to review the gynecologic effects of tamoxifen.
他莫昔芬是一种雌激素拮抗剂,广泛用于乳腺癌患者的辅助治疗。其在提高生存率和降低复发率方面的疗效已在多项欧美研究中得到证实。然而,其作用似乎具有组织特异性。他莫昔芬对子宫内膜、子宫肌层和阴道发挥雌激素作用(激动剂)。在多项安慰剂对照临床试验中已证实子宫癌发病率增加。由于这种药物的广泛使用,及时回顾他莫昔芬的妇科影响是很有必要的。